RT Journal Article
T1 Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
A1 Ríos-Tamayo, Rafael
A1 Martín-García, Agustín
A1 Alarcón-Payer, Carolina
A1 Sánchez-Rodríguez, Dolores
A1 de la Guardia, Ana María Del Valle Díaz
A1 García Collado, Carlos Gustavo
A1 Jiménez Morales, Alberto
A1 Jurado Chacón, Manuel
A1 Cabeza Barrera, José
K1 dexamethasone
K1 multiple myeloma
K1 pomalidomide
K1 triplet therapy
AB Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
YR 2017
FD 2017-08-22
LK http://hdl.handle.net/10668/19499
UL http://hdl.handle.net/10668/19499
LA en
DS RISalud
RD Apr 5, 2025